Investing.com - Gritstone Oncology (NASDAQ: GRTS) reported first quarter EPS of $-0.340, $0.01 worse than the analyst estimate of $-0.330. Revenue for the quarter came in at $1.74M versus the consensus estimate of $1.16M.
Gritstone Oncology's stock price closed at $0.97. It is down -56.760% in the last 3 months and down -63.280% in the last 12 months.
Gritstone Oncology saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Gritstone Oncology's stock price’s past reactions to earnings here.
According to InvestingPro, Gritstone Oncology's Financial Health score is "fair performance".
Check out Gritstone Oncology's recent earnings performance, and Gritstone Oncology's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar